2025 Audi RS e-tron GT Performance Photo Gallery
The Audi RS e-tron GT Performance may look like just another European four-door EV, but put it in Launch Mode and floor it and your brain will wind up bouncing along the pavement somewhere behind you, screaming. Two motors make a combined 912 hp. A sprint from 0 to 60 mph takes 2.4 seconds. Range is 278 miles. Prices start at $168,295 and go over $190,000—but worth it once you try Launch Mode.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Microsoft Expands Security Footprint: Is it the Next Revenue Pillar?
Microsoft's MSFT aggressive expansion into cybersecurity services is gaining momentum as a potential major revenue driver, with the company recently launching its European Security Program and reporting strong growth metrics in its security customer tech giant now serves 1.4 million security customers globally, with over 900,000 utilizing four or more security workloads, representing 21% year-over-year growth. This customer concentration suggests deepening enterprise relationships and higher revenue per customer, critical indicators for sustainable growth in the security European Security Program, announced in Berlin, offers free AI-based threat intelligence sharing to European governments, including all 27 EU member states. While provided at no cost, this strategic move positions Microsoft to capture future commercial opportunities and establishes the company as a trusted security partner across a significant economic integration of artificial intelligence into security operations appears central to Microsoft's strategy. The company processes 84 trillion daily threat signals and has introduced Security Copilot agents designed to autonomously handle high-volume security tasks. This AI-powered approach could differentiate Microsoft's offerings in an increasingly crowded cybersecurity identity service Entra has reached more than 900 million monthly active users, providing a substantial foundation for cross-selling additional security services. The company's multi-workload customer growth suggests successful expansion beyond basic security offerings into comprehensive enterprise cybersecurity threats intensifying globally and organizations increasing security budgets, Microsoft's expanding security portfolio — leveraging its cloud infrastructure and AI capabilities — positions the segment as a potentially significant revenue contributor alongside its established cloud and productivity businesses. Microsoft's 1.4 million security customers contrast sharply with pure-play cybersecurity specialists. CrowdStrike CRWD focuses on premium enterprise segments, with 48% of subscription customers adopting six or more cloud modules, while 32% utilize seven modules and 22% deploy eight or more modules as of April 2025. CrowdStrike's AI-native Falcon platform directly challenges Microsoft's security offerings, though CrowdStrike maintains superior endpoint protection brand recognition. Palo Alto Networks PANW serves more than 80,000 enterprise customers, pursuing platform consolidation strategies similar to Microsoft's multi-workload approach. Palo Alto Networks continues expanding AI capabilities through acquisitions, yet Palo Alto Networks lacks Microsoft's integrated cloud infrastructure advantages for seamless delivery. The Zacks Consensus Estimate for Microsoft's fiscal 2025 revenues is pegged at $278.8 billion, suggesting 13.47% year-over-year growth. The consensus mark for earnings is pegged at $13.33 per share, indicating a 12.97% year-over-year increase. Microsoft Corporation price-consensus-chart | Microsoft Corporation Quote Find the latest EPS estimates and surprises on Zacks Earnings stock's current valuation of 11.09 times forward sales appears to fully account for near-term growth potential, exceeding the Zacks Computer - Software industry average of 9.16 times. Image Source: Zacks Investment Research Shares of Microsoft have returned 10.1% year to date compared with the Zacks Computer & Technology sector's growth of 0.4%. Image Source: Zacks Investment Research MSFT stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Microsoft Corporation (MSFT) : Free Stock Analysis Report Palo Alto Networks, Inc. (PANW) : Free Stock Analysis Report CrowdStrike (CRWD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
ISG to Evaluate Medical Device Service, Solution Providers
Upcoming ISG Provider Lens™ reports will cover providers helping companies integrate new technologies to make devices more capable, compliant and interoperable STAMFORD, Conn., June 05, 2025--(BUSINESS WIRE)--Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, has launched a research study evaluating digital transformation service and solution providers supporting the medical devices industry, exploring how they help device makers address technology challenges while accelerating innovation and time to market. The study results will be published in two comprehensive ISG Provider Lens™ reports, titled Medical Device Digital Services, covering the U.S. and European markets, respectively, and scheduled to be released in November 2025. The study will examine providers offering medical device companies end-to-end digital engineering and product development services; strategic consulting, quality assurance and regulatory compliance services; and digital solutions for post-market activities. In particular, it will assess provider ability to address technology challenges such as data interoperability and cybersecurity. Enterprise buyers will be able to use information from the reports to evaluate their current vendor relationships, potential new engagements and available offerings, while ISG advisors use the information to recommend providers to the firm's buy-side clients. The medical device industry is embracing digital transformation by integrating AI, IoT and cloud technologies. These advancements enhance real-time monitoring and predictive diagnostics, facilitate improved clinical decisions and transform traditional hardware-centric models into dynamic, data-driven ecosystems. "Medical devices are quickly evolving to meet the new requirements of patient-centric healthcare," said Iain Fisher, director, ISG Provider Lens Research. "Device makers need to collaborate with providers on innovation and improve outcomes to remain competitive in the market." ISG has distributed surveys to more than 100 providers of medical device services and solutions. Working in collaboration with ISG's global advisors, the research team will produce three quadrants representing the digital services and solutions most commonly used by medical device companies, based on ISG's experience working with its clients. The three quadrants are: Digital Engineering and Product Development, evaluating providers with expertise in designing and enhancing interconnected, software-driven, compliant medical devices. Providers are assessed on their abilities to apply emerging technologies such as AI, ML, digital twins and edge computing to accelerate innovation, ensure compliance and reduce time to market. Regulatory Compliance, Strategy and Quality Assurance, assessing providers that help medical device manufacturers navigate global regulatory frameworks and align engineering initiatives with go-to-market objectives. Providers implement cybersecurity and data protection strategies, ensuring product and patient safety in connected and software-driven environments. Post-Market Digital Enablement, covering providers that deliver digital solutions for continuous monitoring, device tracking and telehealth integration. Providers focus on developing and integrating remote patient monitoring systems, analytics and post-market surveillance tools. Geographically focused reports from the study will cover digital services and solutions offered to medical device companies in the U.S. and Europe. ISG analysts Rohan Sinha (U.S.) and Sneha Jayanth (Europe) will serve as authors of the reports. A list of identified providers and vendors and further details on the study are available in this digital brochure. Companies not listed as digital transformation solution and service providers can contact ISG and ask to be included in the study. All 2025 ISG Provider Lens™ evaluations feature expanded customer experience (CX) data that measures actual enterprise experience with specific provider services and solutions, based on ISG's continuous CX research. Enterprise customers wishing to share their experience about a specific provider or vendor are encouraged to complete this online survey. Participants will receive a copy of this report in return for their feedback. About ISG Provider Lens™ Research The ISG Provider Lens™ Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG's global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG's enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage. About ISG ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world's top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments. View source version on Contacts Press Contacts: Laura Hupprich, ISG+1 203 517 Julianna Sheridan, Matter Communications for ISG+1 978-518-4520isg@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
CORRECTION - Inspira Scales Up ART100 Production Capabilities Amid Advanced Negotiation with European Government Authority
RA'ANANA, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- RA'ANANA, Israel, June 5, 2025 -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," 'Inspira Technologies,' or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced preparations for scaled-up its production capabilities for its U.S. Food and Drug Administration (FDA)-cleared INSPIRA™ ART100 system (the 'ART100 system'), in response to expected demand from a European governmental authority with which the Company is currently in advanced-stage procurement negotiations. this ramp up strategic production aims to meet near-term delivery needs as Inspira expects these negotiations move toward finalization. The ART100 system, already implemented in clinical settings in the United States, is gaining traction as a reliable device for a critical care and emergency preparedness programs. 'We are preparing for commercial execution,' said Dagi Ben Noon, Chief Executive Officer of Inspira Technologies. 'Our dialogue with a European government body has advanced to a stage where operational readiness is essential. Expanding our production capacity will enable us to meet projected deployment needs quickly and efficiently.' This move follows Inspira's recent announcement of its global rollout strategy and reflects the Company's commitment to fast-track revenue generation from the ART100 system, while continuing its development of its next-generation platforms, the ART500 and the HYLA™ blood sensor. The Company believes the current momentum—combined with a growing global focus on scalable respiratory solutions—may accelerate the Company's emergence as a strategic public health supplier across both governmental and private sectors. About Inspira Technologies Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company's U.S. FDA -cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a technological foundation for the development of the INSPIRA ART500 — a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the critical care and MedTech landscape. The Company's recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: Forward-Looking Statement Disclaimer This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses that it expects demand for its ART100 system from a European governmental authority, that it has ramped up its production in order to meet expected near term delivery needs, , the benefits and advantages of the ART100, that the ART100 system is gaining traction as a reliable device for a critical care and emergency preparedness programs, the potential outcome of its procurement negotiations with a European government authority, its belief that expanding its production capacity enables the Company to meet projected deployment needs quickly and efficiently, and its belief that current momentum may accelerate the Company's emergence as a strategic public health supplier across both governmental and private sectors. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at Company ContactInspira Technologies – Media RelationsEmail: info@ +972-9-9664485Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
